海西新药(02637.HK)：拟不超4亿港元认购金融产品

Core Viewpoint - Hai Xi New Drug (02637.HK) announced its plan to utilize idle funds for investments in structured notes and a fund subscription, indicating a strategic move to enhance its investment portfolio [1] Group 1: Investment Details - The company will invest HKD 200 million in notes issued by Essence Global Investment Limited under its USD 1 billion secured structured note program [1] - Additionally, the company plans to subscribe up to HKD 200 million in the China Rock Fund SPC [1] - The total investment amount for the subscription matters is therefore up to HKD 400 million [1]